

Synthesis of Flavin–Calix[4]arene Conjugate Derivatives

by **Serkan Sayin**^{*a)}, **Gülderem Uysal Akkuş**^{b)}, **Radek Cibulka**^{c)}, **Ivan Stibor**^{c)}, and **Mustafa Yilmaz**^{a)}

^{a)} Department of Chemistry, Selcuk University, TR-Konya-42075

(phone: +903322233873; fax: +903322410106; e-mail: saynserkan@hotmail.com)

^{b)} Department of Chemistry, Afyon Kocatepe University, TR-Afyonkarahisar-03200

^{c)} Department of Organic Chemistry, Institute of Chemical Technology, Technická 5 CZ-16628-Prague 6

The synthesis of two new flavin substituted calix[4]arene derivatives, **9** and **10**, is described. The first flavin substituted calix[4]arene derivative **9** was synthesized by the reaction of 3-methylalloxazine (**5**) with 25,27-bis(3-bromopropoxy)-26,28-dihydroxy-5,11,17,23-tetra(*tert*-butyl)calix[4]arene (**4**) in high yield (92%). The other derivative **10** was prepared from 3-methylalloxazine-1-acetic acid (**7**) and 25,27-bis(3-cyanopropoxy)calix[4]arene (**3**). All new compounds were characterized by a combination of FT-IR and ¹H-NMR spectroscopy, and elemental-analysis techniques.


Introduction. – Flavins play an important role in living organisms [1], and they are involved in several important photobiological and photochemical processes, such as phototropism, phototaxis, and photodynamic action [2][3]. Since 1966, the photochemistry and photophysics of alloxazine derivatives have been studied, due to the discovery of the proton-transfer reactions in lumichrome and related compounds [4][5]. It is well-known that substituted alloxazine (= benzo[*g*]pteridine-2,4(1*H*,3*H*)-dione) derivatives, mainly lumichromes, are present in many foods and formed in the normal metabolic process of ingested riboflavin [6]. Recently, alloxazines have attracted attention due to realization of their possible involvement in a wide variety of biological systems [6][7]. For instance, it has been shown that lumichrome may be used to inhibit flavin reductase in living *Escherichia coli* cells [8].

Supramolecular science has been developed tremendously over the past 30 years [9][10]. It is known that preorganization and cooperativeness of multifunctional groups play a major role in biological reaction kinetics [11]. Some calix[4]arene derivatives, which bear azo groups [12], guanidium units [13], or nucleoside hybrids [11], are compounds which can be used as enzymes in the cell. At the same time, flavins that are obtained by condensation between α -phenylenediamine and alloxane [14] are involved in several biological processes [15]. These are generally redox cofactors involved in electron redox processes [16] of enzymatic reactions [17][18]. To this end, we considered that compounds containing both flavin and calixarene units, *i.e.*, **9** and **10**, respectively, might have interesting biological activities. Here, we report the first synthesis of calixarene derivatives that contain flavin units.

Results and Discussion. – *Synthesis.* The calix[4]arenes can be functionalized with desired groups both at the upper and the lower rim [19][20] in order to obtain appropriate arrangements or to achieve the preorganized conformation [9].


The aim of this work was the design and synthesis of new calix[4]arene derivatives, which are cited as flavin–conjugate calixarene derivatives. All new compounds were characterized by means of ^1H -NMR and IR spectroscopy, and elemental analyses. The synthetic routes leading to new calixarene derivatives are depicted in *Schemes 1* and *2*.

Scheme 1. The Synthetic Route for the Preparation of **3** and **4**



i) AlCl_3 , PhOH, toluene, r.t., 78%. *ii*) K_2CO_3 , MeCN, $\text{Cl}(\text{CH}_2)_3\text{CN}$, reflux, 79%. *iii*) 1,3-Dibromopropane, K_2CO_3 , MeCN, reflux, 64%.

p-(*tert*-Butyl)calix[4]arene **1** was chosen as the starting material, and it was transformed to the derivatives **3** and **4** according to known procedures [19][21][22] (see *Scheme 1*). The flavin part of the molecules was synthesized starting from compound **5**, which is available by condensation of benzene-1,2-diamine with *N*-methylalloxane according to the procedure described in [14]. Treatment of **5** with $\text{BrCH}_2\text{COOEt}$ afforded ethyl 3-methylalloxazine-1-acetate (**6**; *Scheme 2*). Then, upon hydrolysis of **6** with HCl, the flavin-carboxylic acid **7** was obtained. Treatment of **7** with SOCl_2 at 45° for 2 h yielded the Cl derivative **8**. The substitution of *p*-(*tert*-butyl)calix[4]arene derivative (**4**) at its bromoalkoxy chains was conducted in the presence of K_2CO_3 in DMF under N_2 with flavin to afford the cone conformer flavin–calix[4]arene conjugate **9** in high yield (92%). The other flavin–calix[4]arene conjugate **10** was synthesized by treatment of 1-(2-chloro-2-oxoethyl)-3-methylalloxazine (**8**) with 25,27-bis(3-cyanopropoxy)calix[4]arene (**3**) in MeCN in the presence of K_2CO_3 at 85° for 37 h in 42% yield. The ^1H -NMR spectra of **9** and **10** display a typical *AX* pattern for the H-atoms of a CH_2 bridge (ArCH_2Ar) of the calixarene moiety at $\delta(\text{H})$ 4.17 and 3.5 ppm ($J = 12.8$)

Scheme 2. The Synthetic Route for the Preparation of **9** and **10**

i) $\text{BrCH}_2\text{COOEt}$, K_2CO_3 , DMF, r.t., 77%. ii) HCl , $80-90^\circ$, 55%. iii) SOCl_2 , 45° . iv) **4**, NaI , K_2CO_3 , DMF, N_2 , r.t., 92%. v) **3**, MeCN , K_2CO_3 , 85° , 42%.

for **10**, and 4.11 ppm ($J = 12.8$) for **9**, indicating that compounds **9** and **10** exist in the cone conformation [23].

Conclusions. – We have synthesized two new calix[4]arene derivatives which contain flavin units at the lower rim of calix[4]arene. The structures of flavin–calix[4]arene conjugates have been established by means of IR and ^1H -NMR spectroscopy, and elemental analyses.

It is well-known that the compounds which have N and O donor atom groups are able to inhibit the enzyme production [24]; therefore, **9** and **10**, which have several donor atoms, potentially could inhibit the enzyme production, and their biological

activity could be investigated *in vivo* and *in vitro*. In conclusion, **9** and **10** may be used for numerous applications in the medicinal area.

We thank the *Scientific and Technical Research Council of Turkey* (TUBITAK – Grant No. TBAG AY/396) for financial support of this work.

Experimental Part

General. Solvents were dried by storing them over molecular sieves (Aldrich; 4 Å, 8–12 mesh). Toluene was dried with CaH₂ and stored over Na wire. DMF was dried with CaSO₄ and stored over molecular sieves. The drying agents employed during workup were Na₂SO₄ and MgSO₄. All aq. solns. were prepared with deionized H₂O that had been passed through a Milli-Q Plus water purification system. Starting materials and reagents were obtained from Aldrich, Lancaster, and Fluka and were used without further purification. TLC: DC Alufolien Kieselgel 60 F₂₅₄ (Merck). M.p.: Barnsted/Electro thermal apparatus in a sealed capillaries; uncorrected. IR Spectra: Perkin-Elmer 1605 FTIR System Spectrum BX spectrometer; as KBr pellets. ¹H-NMR Spectra: Varian 400 MHz and Varian Mercury Plus 300 MHz spectrometers; chemical shifts in ppm rel. to TMS (δ = 0.0 ppm). Elemental analyses (C, H, N): Perkin-Elmer 240 analyzer.

Syntheses. 5,11,17,23-Tetra(tert-butyl)-25,26,27,28-tetrahydroxycalix[4]arene (**1**), 25,26,27,28-tetrahydroxycalix[4]arene (**2**), 25,27-bis(3-cyanopropoxy)-26,28-dihydroxycalix[4]arene (**3**), 25,27-bis(3-bromopropoxy)-5,11,17,23-tetra(tert-butyl)-26,28-dihydroxycalix[4]arene (**4**), and 3-methylalloxazine (**5**) were synthesized according to literature procedures [14][19][21][22]. Ethyl (3-methylalloxazin-1-yl)acetate (**6**), (3-methylalloxazin-1-yl)acetic acid (**7**), (3-methylalloxazin-1-yl)acetyl chloride (**8**), and the final products flavin–calix[4]arene **9** and flavin–calix[4]arene conjugates **9** and **10**, resp., were prepared for the first time according to the procedures described below.

25,27-Bis(3-cyanopropoxy)-26,28-dihydroxycalix[4]arene (=4,4'-[26,28-Dihydroxypentacyclo[19.3.1.1^{3,7}.1^{9,13}.1^{15,19}]octacosa-1(25),3(28),4,6,9(27),10,12,15(26),16,18,21,23-dodecaene-25,27-diyl]bis(oxy)]dibutanenitrile; **3**). Prepared according to [21]. Yield 79%. M.p. 244–246°. IR (KBr): 2363 (CN). ¹H-NMR (CDCl₃, 400 MHz): 2.39 (quint., *J* = 8.0, 2 CH₂CH₂CN); 3.08 (*t*, *J* = 7.2, 2 CH₂CN); 3.47 (*d*, *J* = 12.8, 2 ArCH₂Ar); 4.13 (*t*, *J* = 5.6, 3 OCH₂CH₂); 4.21 (*d*, *J* = 12.8, 2 ArCH₂Ar); 6.70 (*t*, *J* = 7.2, 2 arom. H); 6.79 (*t*, *J* = 7.2, 2 arom. H); 6.94 (*d*, *J* = 7.2, 4 arom. H); 7.09 (*d*, *J* = 7.2, 4 arom. H); 7.79 (*s*, 2 OH). Anal. calc. for C₃₆H₃₄N₂O₄ (558.68): C 77.40, H 6.13, N 5.01; found: C 77.01, H 6.22, N 4.92.

25,27-Bis(3-bromopropoxy)-5,11,17,23-tetra(tert-butyl)-26,28-dihydroxycalix[4]arene (=26,28-Bis(3-bromopropoxy)-5,11,17,23-tetra(tert-butyl)pentacyclo[19.3.1.1^{3,7}.1^{9,13}.1^{15,19}]octacosa-1(25),3(28),4,6,9(27),10,12,15(26),16,18,21,23-dodecaene-25,27-diol; **4**). Prepared according to [22]. Yield 64%. M.p. 277–279°. ¹H-NMR (CDCl₃, 300 MHz): 7.05 (*s*, 4 arom. H); 4.32 (*d*, *J* = 13.3, ArCH₂Ar); 4.28 (*t*, *J* = 5.6, 2 CH₂O); 3.83 (*t*, *J* = 6.4, 2 CH₂Br); 3.32 (*d*, *J* = 13.3, 2 ArCH₂Ar); 1.29 (*s*, 2 *t*-Bu); 0.94 (*s*, 2 *t*-Bu). Anal. calc. for C₅₀H₆₆Br₂O₄ (890.88): C 67.41, H 7.47, Br 17.94; found: C 67.53, H 7.50, Br 17.93.

3-Methylalloxazine (=3-Methylbenzo[g]pteridine-2,4(1H,3H)-dione; **5**). Prepared according to [14]. Yield: 65%. M.p. 285°. ¹H-NMR ((D₆)DMSO, 300 MHz): 3.29 (*s*, MeN); 7.74–7.79 (*m*, 1 arom. H); 7.92 (*d*, *J* = 3.5, 2 arom. H); 8.18 (*d*, *J* = 8.2, 1 arom. H); 12.23 (*s*, NH). Anal. calc. for C₁₁H₈N₄O₂ (228.21): C 55.77, H 3.81, N 23.65; found: C 56.12, H 3.41, N 23.55.

Ethyl (3-Methylalloxazin-1-yl)acetate (=Ethyl (3-Methyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-1(2H)-yl)acetate; **6**). A mixture of **5** (0.3 g, 1.315 mmol), K₂CO₃ (1 g, 7.303 mmol), and BrCH₂COOEt (2.195 g, 13.146 mmol) were stirred for 5 h in DMF (110 ml) at r.t. Then, the solvent was removed *in vacuo*, and the yellow product was crystallized from CH₂Cl₂/Et₂O. Yield: 0.318 g (77%). M.p. 205–207°. ¹H-NMR ((D₆)DMSO, 400 MHz): 1.31 (*t*, *J* = 6.9, Me); 3.62 (*s*, MeN); 4.26 (*q*, *J* = 7.5, CH₂O); 5.20 (*s*, CH₂N); 7.77 (*t*, *J* = 7.8, 1 arom. H); 7.89 (*t*, *J* = 6.8, 1 arom. H); 7.99 (*d*, *J* = 7.7, 1 arom. H); 8.36 (*d*, *J* = 8.2, 1 arom. H). Anal. calc. for C₁₅H₁₄N₄O₄ (314.3): C 57.32, H 4.49, N 17.83; found: C 57.57, H 4.32, N 17.78.

(3-Methylalloxazin-1-yl)acetic Acid (=3-Methyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-1(2H)-yl)-acetic Acid; **7**). A mixture of **6** (0.318 g, 1.012 mmol) and HCl (5 ml) was stirred at 80–90° for 105 min. The mixture was cooled, and ice-water (15 ml) was added to the soln. The yellow solid that precipitated was filtered off and washed with H₂O. Reprecipitation from 2N AcOH gave **7** as a light yellow solid.

Yield: 0.158 g (55%). M.p. 289–293°. ¹H-NMR ((D₆)DMSO, 400 MHz): 3.31 (s, MeN); 4.98 (s, CH₂N); 7.85 (t, *J* = 6.3, 1 arom. H); 8.00 (d, *J* = 5.1, 2 arom. H); 8.26 (d, *J* = 7.8, 1 arom. H); 13.15 (s, OH). Anal. calc. for C₁₃H₁₀N₄O₄ (286.24): C 54.55, H 3.52, N 19.57; found: C 54.67, H 3.45, N 19.53.

(3-Methylalloxazin-1-yl)acetyl Chloride (= (3-Methyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-1(2H)-yl)acetyl Chloride; **8**). Compound **7** (1.00 g, 0.350 mmol) was added to SOCl₂ (2.5 ml, 31.903 mmol), and the suspension was stirred at 45°. After 2 h, the solid had dissolved, SOCl₂ was evaporated at < 45°, and the crude chloride **8** obtained was used without further purification.

1,1'-[5,11,17,23-Tetra-(tert-butyl)-26,28-dihydroxypentacyclo[19.3.1.1^{3,7}.1^{9,13}.1^{15,19}]octacosa-1(25),3(28),4,6,9(27),10,12,15(26),16,18,21,23-dodecaene-25,27-diyl]bis(oxypropane-3,1-diyl)]bis(3-methylbenzo[g]pteridine-2,4(1H,3H)-dione); **9**). K₂CO₃ (0.6 g), **5** (0.438 mmol), and NaI (0.4 g) were added to a soln. of **4** (0.219 mmol) in 20 ml of dry DMF, and the mixture was stirred under N₂ at r.t. for 47 h. The reaction was monitored by TLC. The salts were filtered off, and the solvent from the filtrate was removed under reduced pressure. Then, Et₂O was added, the precipitates formed were filtered off, and the received product was dried in a vacuum desiccator. Yield 92%. M.p. > 350°. ¹H-NMR ((D₆)DMSO, 400 MHz): 8.53 (s, 2 OH); 8.07–7.93 (*m*, 4 arom. H); 7.76–7.76 (*m*, 2 arom. H); 7.58–7.48 (*m*, 2 arom. H); 7.10 (br. s, 8 arom. H); 4.62 (t, *J* = 6.4, 2 CH₂O); 4.11 (d, *J* = 12.8, 2 ArCH₂Ar); 4.0 (t, *J* = 5.2, 2 CH₂N); 3.35 (overlapped with DMSO, this area should correspond to 10 H-atoms belonging to ArCH₂Ar and MeN); 2.32–2.29 (*m*, 2 CH₂); 1.16 (s, 2 *t*-Bu); 1.10 (s, 2 *t*-Bu). Anal. calc. for C₇₂H₈₀N₈O₈ (1185.45): C 72.95, H 6.80, N 9.45; found: C 73.02, H 6.88, N 9.32.

26,28-Bis(3-cyanopropoxy)pentacyclo[19.3.1.1^{3,7}.1^{9,13}.1^{15,19}]octacosa-1(25),3(28),4,6,9(27),10,12,15(26),16,18,21,23-dodecaene-25,27-diyl Bis[(3-methyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-1(2H)-yl)acetate]; **10**). A mixture of **8** (0.11 g, 0.36 mmol), **3** (0.09 g, 0.164 mmol), and K₂CO₃ (0.10 g, 0.724 mmol) in MeCN (6 ml) was stirred at 85° for 37 h. After cooling, MeCN was removed to dryness, and the residue was dissolved in CH₂Cl₂, washed with H₂O (5 × 30 ml), dried (Na₂SO₄), and then concentrated to a third of the original volume on a rotary evaporation. The residue was then mixed with EtOH. Precipitated **10** was filtered off and dried under vacuum. Yield: 75 mg (42%). M.p. 340°. IR (KBr disk): 1740 (ester C=O). ¹H-NMR ((D₆)DMSO, 400 MHz): 2.32 (*quint.*, *J* = 6.1, 2 CH₂CH₂CN); 3.10 (t, *J* = 7.0, 2 CH₂CN); 3.36 (s, 2 MeN); 3.49 (d, *J* = 12.8, 2 ArCH₂Ar); 4.07 (t, *J* = 5.6, 2 CH₂O); 4.17 (d, *J* = 12.8, 2 ArCH₂Ar); 5.77 (s, 2 CH₂N); 6.63 (t, *J* = 7.5, 2 arom. H); 6.82 (t, *J* = 7.5, 2 arom. H); 7.08 (d, *J* = 7.6, 4 arom. H); 7.18 (d, *J* = 7.5, 4 arom. H); 7.80–7.83 (*m*, 2 arom. H); 8.01 (d, *J* = 2.3, 2 arom. H); 8.24 (d, *J* = 7.9, 4 arom. H). Anal. calc. for C₆₂H₅₀N₁₀O₁₀ (1095.14): C 68.00, H 4.60, N 12.79; found: C 67.97, H 4.51, N 12.93.

REFERENCES

- [1] V. Massey, *Biochem. Soc. Trans.* **2000**, *28*, 283.
- [2] M. Sikorski, D. Prukała, M. Insińska-Rak, I. Khmelinskii, D. R. Worrall, S. L. Williams, J. Hernando, J. L. Bourdelande, J. Koput, E. Sikorska, *J. Photochem. Photobiol., A* **2008**, *200*, 148.
- [3] H. I. Ali, N. Ashida, T. Nagamatsu, *Bioorg. Med. Chem.* **2008**, *16*, 922.
- [4] J. Kozioł, *Photochem. Photobiol.* **1966**, *5*, 41.
- [5] E. Sikorska, I. V. Khmelinskii, S. L. Williams, D. R. Worrall, J. R. Herance, J. L. Bourdelande, J. Koput, M. Sikorski, *J. Mol. Struct.* **2004**, *697*, 199.
- [6] J. Chastain, D. B. McCormick, 'Flavin Metabolites', in 'Chemistry and Biochemistry of Flavoenzymes', Ed. F. Muller, CRC Press, Boston, 1991, p. 196.
- [7] P. F. Heelis, *Chem. Soc. Rev.* **1982**, *11*, 15.
- [8] O. Cunningham, M. G. Gore, T. J. Mantle, *Biochem. J.* **2000**, *345*, 393.
- [9] C.-C. Zeng, Q.-Y. Zheng, Y.-L. Tang, Z.-T. Huang, *Tetrahedron* **2003**, *59*, 2539.
- [10] S. Sayin, F. Özcan, M. Yilmaz, *J. Hazard. Mater.* **2010**, *178*, 312.
- [11] S. J. Kim, B. H. Kim, *Tetrahedron Lett.* **2002**, *43*, 6367.
- [12] T. Haino, M. Nakamura, N. Kato, M. Hiraoka, Y. Fukazawa, *Tetrahedron Lett.* **2004**, *45*, 2281.
- [13] F. Sansone, M. Dudič, G. Donofrio, C. Rivetti, L. Baldini, A. Casnati, S. Cellai, R. Ungaro, *J. Am. Chem. Soc.* **2006**, *128*, 14528.

- [14] K. Bergstad, J.-E. Bäckvall, *J. Org. Chem.* **1998**, *63*, 6650.
- [15] A. J. Robak, B. P. Branchaud, *Tetrahedron Lett.* **2005**, *46*, 5651.
- [16] R. Cibulká, L. Baxová, H. Dvořáková, F. Hampl, P. Měnová, V. Mojz, B. Plancq, S. Sayin, *Collect. Czech. Chem. Commun.* **2009**, *74*, 973.
- [17] R. B. Silverman, 'The organic chemistry of enzyme-catalyzed reactions', Academic Press, London, 2002, pp. 119–146.
- [18] J. McMurray, T. Begley, 'The organic chemistry of biological pathways', Roberts and Company, Colorado, 2005, pp. 109–111.
- [19] C. D. Gutsche, M. Iqbal, *Org. Synth.* **1990**, *68*, 234.
- [20] C. D. Gutsche, M. Iqbal, D. Stewart, *J. Org. Chem.* **1986**, *51*, 742.
- [21] E. M. Collins, M. A. McKervey, E. Madigan, M. B. Moran, M. Owens, G. Ferguson, S. J. Harris, *J. Chem. Soc., Perkin Trans. 1* **1991**, 3137.
- [22] Z.-T. Li, G.-Z. Ji, C.-X. Zhao, S.-D. Yuan, H. Ding, C. Huang, A.-L. Du, M. Wei, *J. Org. Chem.* **1999**, *64*, 3572.
- [23] C. Jaime, X. de Mendoza, P. Prados, P. M. Nieto, C. Sanchez, *J. Org. Chem.* **1991**, *56*, 3372.
- [24] M. A. Kőroğlu, I. Erol, E. Korcan, M. Konuk, *J. Macromol. Sci. Part A: Pure Appl. Chem.* **2007**, *44*, 817.

Received May 5, 2010